| | | | | | | | | | |
|
| |
|
| Dockets Entered
On APril 17, 2006
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 1997P-0498
|
| Label foods & beverages containing greater than 5mg caffeine
|
|
|
|
|
| 1997S-0163
|
| Dietary Supplements, Courtesy Letters (Letters of Objection)
|
|
|
|
|
| 1998P-0724
|
| Prohibition of Cochineal Extract and Carmine Color Additives
|
|
|
|
|
| 1999N-4282
|
| Biotechnology in the Year 2000 and Beyond; Public Meetings
|
|
|
|
|
| 1999P-1340
|
| Declared Eternity eau de Parfum Misbranded
|
|
|
|
|
| 2000P-1211
|
| Establish Mandatory Pre-Market Safety Testing for GE Foods
|
|
|
|
|
| 2001P-0345
|
| Listing the color additive yellow #5 for use in food/Drug
|
|
|
|
|
| 2002D-0325
|
| Polyvinychloride using Plasticier di-(2-ethyhexyl)phthalate
|
|
|
|
|
| 2002N-0273
|
| Animal Proteins Prohibited in Ruminant Feed
|
|
|
|
|
| 2002P-0317
|
| Recall Aspartame as a Neurotoxic Drug
|
|
|
|
|
| 2003N-0076
|
| Food Labeling: Trans Fatty Acids in Nutrition Labeling; Consumer research to consider possible footnote statements
|
|
|
|
|
| 2004N-0355
|
| Scientific Considerations Related to Developing Follow-on Protein Products
|
|
|
|
|
| 2004P-0457
|
| Reclassifcation of the Buechel-Pappas Unconstrained Ankle Prosthesis
|
|
|
|
|
| 2005H-0271
|
| Civil Money Penalty: TMJ Implants, Inc.
|
|
|
|
|
| 2005P-0459
|
| To enforce ban on carbon monoxide gas in fresh meat packaging
|
|
|
|
|
| 2006D-0044
|
| Guidance for Industry on Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims
|
|
|
|
|
| 2006D-0066
|
| Guidance for Industry and FDA Staff: Whole Grains Label Statements
|
|
|
|
|
| 2006N-0019
|
| Orthopedic Devices; Reclassification of the Intervertebral Body Fusion Device
|
|
|
|
|
| 2006N-0029
|
| Agency Information Collection Activities; Proposed Collection; Comment Request; Impact of Coupons on Consumer Perceptions of Products in Prescription Drugs in Direct-to-Consumer Prescription Drug Prin
|
|
|
|
|
|
| 2006N-0106
|
| New Animal Drugs; Adamantane and Neuraminidase Inhibitor Anti-influenza Drugs; Extralabel Animal Drug Use; Order of Prohibition
|
|
|
|
|
| 2006P-0090
|
| Immediately begin the phased removal from the market of propoxyphene (Darvon) and all propoxyphene-containing products.
|
|
|
|
|
| 1997P-0498
|
| Label foods & beverages containing greater than 5mg caffeine
|
|
|
|
|
| EMC 7
|
| B. Crum
|
| Vol #:
|
| 1
|
|
|
|
|
| 1997S-0163
|
| Dietary Supplements, Courtesy Letters (Letters of Objection)
|
|
|
|
|
| LET 870
|
| FDA/CFSAN to Natural Factors Nutritional Products Inc
|
| Vol #:
|
| 26
|
|
|
|
|
| LET 871
|
| FDA/CFSAN to NuraMD
|
| Vol #:
|
| 26
|
|
|
|
|
| LET 872
|
| FDA/CFSAN to Advanced Cardiac Life Sciences LLC
|
| Vol #:
|
| 26
|
|
|
|
|
| LET 873
|
| FDA/CFSAN to New Century Company
|
| Vol #:
|
| 26
|
|
|
|
|
| LET 874
|
| FDA/CFSAN to Food Science Corporation
|
| Vol #:
|
| 26
|
|
|
|
|
| LET 875
|
| FDA/CFSAN to Sedona Laboratories Inc
|
| Vol #:
|
| 26
|
|
|
|
|
| 1998P-0724
|
| Prohibition of Cochineal Extract and Carmine Color Additives
|
|
|
| C 10
|
| L. Oliver
|
| Vol #:
|
| 1
|
|
|
|
|
| EMC 23
|
| D. Joyant
|
| Vol #:
|
| 3
|
|
| | | | | | | | |
|
| |
|
| 1999N-4282
|
| Biotechnology in the Year 2000 and Beyond; Public Meetings
|
|
|
|
|
| C 18261
|
| B. Martyn
|
| Vol #:
|
| 516
|
|
|
|
|
| C 18262
|
| J. Reinhold
|
| Vol #:
|
| 516
|
|
| |
|
| 1999P-1340
|
| Declared Eternity eau de Parfum Misbranded
|
|
|
|
|
| EMC 640
|
| J. Sverdlove
|
| Vol #:
|
| 24
|
|
|
|
|
| 2000P-1211
|
| Establish Mandatory Pre-Market Safety Testing for GE Foods
|
|
|
|
|
| C 12854
|
| B. Martyn
|
| Vol #:
|
| 806
|
|
|
|
|
| C 12855
|
| J. Reinhold
|
| Vol #:
|
| 806
|
|
|
|
|
| 2001P-0345
|
| Listing the color additive yellow #5 for use in food/Drug
|
|
|
|
|
| EMC 1318
|
| M. King
|
| Vol #:
|
| 6
|
|
|
|
|
| 2002D-0325
|
| Polyvinychloride using Plasticier di-(2-ethyhexyl)phthalate
|
|
|
|
|
| EMC 245
|
| K. Pickens
|
| Vol #:
|
| 4
|
|
|
|
|
| 2002N-0273
|
| Animal Proteins Prohibited in Ruminant Feed
|
|
|
|
|
| C 536
|
| C. Holland, Sr.
|
| Vol #:
|
| 45
|
|
|
|
|
| 2002P-0317
|
| Recall Aspartame as a Neurotoxic Drug
|
|
|
|
|
| EMC 632
|
| Calorie COntrol Council
|
| Vol #:
|
| 9
|
|
|
|
|
| EMC 633
|
| Mission Possible International
|
| Vol #:
|
| 9
|
|
|
|
|
| EMC 634
|
| Mission Possible International
|
| Vol #:
|
| 9
|
|
|
|
|
| EMC 635
|
| Mission Possible International
|
| Vol #:
|
| 9
|
|
|
|
|
| 2003N-0076
|
| Food Labeling: Trans Fatty Acids in Nutrition Labeling; Consumer research to consider possible footnote statements
|
|
|
|
|
| EMC 1271
|
| P. Eaton
|
| Vol #:
|
| 12
|
|
|
|
|
| EMC 1272
|
| P. Eaton
|
| Vol #:
|
| 12
|
|
|
|
|
| EMC 1273
|
| E. Sforza
|
| Vol #:
|
| 12
|
|
|
|
|
| EMC 1274
|
| D. Buffetta, Jr.
|
| Vol #:
|
| 12
|
|
|
|
|
| EMC 1275
|
| J. Schaures
|
| Vol #:
|
| 12
|
|
| |
|
| 2004N-0355
|
| Scientific Considerations Related to Developing Follow-on Protein Products
|
|
|
|
|
| EMC 9
|
| Eli Lilly and Company (Lilly)
|
| Vol #:
|
| 5
|
|
|
|
|
| 2004P-0457
|
| Reclassifcation of the Buechel-Pappas Unconstrained Ankle Prosthesis
|
|
|
|
|
| LET 3
|
| HFZ-001 to Endotec, Incorporated
|
| Vol #:
|
| 2
|
|
|
|
|
| 2005H-0271
|
| Civil Money Penalty: TMJ Implants, Inc.
|
|
|
|
|
| CS 9
|
| HFA-305
|
| Vol #:
|
| 3
|
|
| | | | | | | | |
|
| |
|
| MO 8
|
| GCF-1
|
| Vol #:
|
| 3
|
|
|
|
|
| OR 9
|
| HF-3
|
| Vol #:
|
| 3
|
|
| |
|
| 2005P-0459
|
| To enforce ban on carbon monoxide gas in fresh meat packaging
|
|
|
|
|
| C 5
|
| E. Moe
|
| Vol #:
|
| 2
|
|
|
|
|
| C 6
|
| Precept Food, LLC
|
| Vol #:
|
| 2
|
|
|
|
|
| 2006D-0044
|
| Guidance for Industry on Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims
|
|
|
|
|
| C 14
|
| Sanofi-aventis US, Inc.
|
| Vol #:
|
| 1
|
|
|
|
|
| C 15
|
| Hoffmann-La Roche, Inc.
|
| Vol #:
|
| 1
|
|
|
|
|
| C 16
|
| Society for Clinical Data Management, Inc. (SCDM)
|
| Vol #:
|
| 1
|
|
|
|
|
| 2006D-0066
|
| Guidance for Industry and FDA Staff: Whole Grains Label Statements
|
|
|
|
|
| C 6
|
| Whole Grains Council
|
| Vol #:
|
| 1
|
|
|
|
|
| C 7
|
| Barilla America, Inc. (Barilla)
|
| Vol #:
|
| 1
|
|
|
|
|
| C 8
|
| AmeriFlax
|
| Vol #:
|
| 1
|
|
|
|
|
| C 9
|
| Whole Gain Connection
|
| Vol #:
|
| 1
|
|
|
|
|
| 2006N-0019
|
| Orthopedic Devices; Reclassification of the Intervertebral Body Fusion Device
|
|
|
|
|
| C 3
|
| Orthopedic Surgical Maufacturers Association (OSMA)
|
| Vol #:
|
| 2
|
|
|
|
|
| 2006N-0029
|
| Agency Information Collection Activities; Proposed Collection; Comment Request; Impact of Coupons on Consumer Perceptions of Products in Prescription Drugs in Direct-to- Consumer Prescription Drug Prin
|
|
|
|
|
|
|
|
|
| C 2
|
| Greenlining Institute
|
| Vol #:
|
| 1
|
|
|
|
|
| 2006N-0106
|
| New Animal Drugs; Adamantane and Neuraminidase Inhibitor Anti-influenza Drugs; Extralabel Animal Drug Use; Order of Prohibition
|
|
|
|
|
| EMC 2
|
| American Veterinary Medical Association (AVMA)
|
| Vol #:
|
| 2
|
|
|
|
|
| 2006P-0090
|
| Immediately begin the phased removal from the market of propoxyphene (Darvon) and all propoxyphene-containing products.
|
|
|
|
|
| C 1
|
| Xanodyne Pharmaceuticals, Inc. (Xanodyne)
|
| Vol #:
|
| 1
|
|
